As always, when you continue to post here nonstop 24/7 (even on weekends and holidays) we know this is a great investment. Your presence here gives many comfort. It’s really quite interesting, isn’t it. :)
The fudster is unable to grasp the idea of crossover efficacy. The crossover efficacy resulted in rGBM efficacy. Basic problem with the fudster is his lack of grasp of the JAMA data which shows hitherto never-before nGBM and rGBM efficacy. The fudster can keep on making senseless noise, but nobody would pay any attention to it, because no one can argue against data. The fudster doesn't want to grasp it because he is a fudster.
Clearly you keep intentionally ignoring what impact the six ltfu (likely early), in the control group of 99 patients, could have on the original endpoint analysis comparison for survival if they were located. Saying over and over with absolute certainty that endpoint has utterly failed is just a self-inflicted wound on your part.
Market Data 
Markets 
AI
